Also known as Velcade
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.Source: Wikipedia
Estimated Total Cost: $4980.08 for an average of 21 days supply
Patients are most commonly prescribed bortezomib to treat multiple myeloma, coronary atherosclerosis, kidney failure, and rabies.
Patients taking bortezomib most commonly experience side effects like weakness, nausea, and diarrhea.
|Peripheral nerve disorder (Peripheral Neuropathy)|
|Cramps and spasms|
|Shortness of breath|
|Itching of skin|
|Itching of unknown cause|
|Shingles (herpes zoster) (Zoster)|
|Bones are painful|